Report subject
Caremark Rx, LLCPharmacy benefit manager named in FTC study and administrative complaint records.
Source-specific evidence
The FTC interim report identifies Caremark Rx among the six PBMs that received Section 6(b) orders.
Official record dossierMonitoringReport
FTC releases interim staff report on prescription drug middlemen
The FTC published interim findings on PBM concentration and vertical integration, including aggregate shares for the largest PBMs.
Supplies top-three and top-six concentration facts while leaving individual firm shares unavailable; Antitrust Radar therefore continues to withhold HHI.
Official recordFTC releases interim staff report on prescription drug middlemenReport / Federal Trade Commission / 1 market
- Record identityevt-pbm-interim-report-2024Jul 9, 2024
- Official scopeReportFederal Trade Commission
- Market scope1 linked contextSeparately bounded profiles
- Permitted inferenceChronology + contextNo automatic causal claim
Exact named-organization edges
Who this official record names
Report subject
Express Scripts, Inc.Pharmacy benefit manager named in FTC study and administrative complaint records.
Source-specific evidence
The FTC interim report identifies Express Scripts among the six PBMs that received Section 6(b) orders.
Report subject
Humana Pharmacy Solutions, Inc.Pharmacy benefit manager named as a recipient of an FTC Section 6(b) order discussed in the interim staff report.
Source-specific evidence
The FTC interim report identifies Humana Pharmacy Solutions among the six PBMs that received Section 6(b) orders.
Report subject
MedImpact Healthcare Systems, Inc.Pharmacy benefit manager named as a recipient of an FTC Section 6(b) order discussed in the interim staff report.
Source-specific evidence
The FTC interim report identifies MedImpact among the six PBMs that received Section 6(b) orders.
Report subject
OptumRx, Inc.Pharmacy benefit manager named in FTC study and administrative complaint records.
Source-specific evidence
The FTC interim report identifies OptumRx among the six PBMs that received Section 6(b) orders.
Report subject
Prime Therapeutics LLCPharmacy benefit manager named as a recipient of an FTC Section 6(b) order discussed in the interim staff report.
Source-specific evidence
The FTC interim report identifies Prime Therapeutics among the six PBMs that received Section 6(b) orders.
A relationship means an official source names the organization in connection with the dated record. It does not by itself establish liability, market power, ownership, control, or that the organization participates in every market linked to that record.
Descriptive economic context
Public HHI evidence around this date
Each row searches one linked market profile for strict pre-event, same-year, and strict post-event observations. Missing anchors remain part of the result.
0Paired
0One-sided
1Unavailable
- Strict pre
- Unavailable
- No earlier HHI
- Event year
- Unavailable
- No same-year HHI
- Strict post
- Unavailable
- No later HHI
- Pre-post change
- Not available
- Pair not available
Before/after HHI differences are descriptive comparisons between discrete public releases. They do not estimate the causal effect of the policy event.
Bounded market context
Markets linked to this record
United States / Health care
HHI unavailablePBMs
Pharmacy benefit management services profile based on FTC public findings. The FTC reports top-three and top-six aggregate shares but not enough individual PBM market shares in the public press-release record to compute HHI.
A linked market identifies the observatory context assigned to this record. It is not necessarily the relevant antitrust market alleged or adjudicated in the official matter.
Source custody
Official source behind the record
Federal Trade Commission / agency report
Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies
FTC interim staff report and press release on PBM concentration and vertical integration.
Accessed May 16, 2026. Federal Trade Commission, FTC Releases Interim Staff Report on Prescription Drug Middlemen, July 9 2024.
License note: Public federal government report
Nearby observatory chronology
Other records sharing these market contexts
Explicit proceeding membership / record 1 of 1
FTC pharmacy benefit manager market study
Open the declared chronology before using market-linked nearby records as broader context.
Jul 14, 2026
RemedyFeb 4, 2026
RemedyFederal Trade Commission
FTC announces proposed consent agreement with Express ScriptsShared context: PBMs
Sep 20, 2024
LitigationFederal Trade Commission
FTC files administrative complaint against the three largest PBMsShared context: PBMs
This chronology is generated from shared observatory market links. It does not assert that the records concern the same matter, conduct, parties, or theory of harm.
Reproducible record packet
Reuse this record and its joins
Filtered routes preserve the exact event ID across the official record, named-organization edges, descriptive market windows, and linked market profiles.
- Event ID
- evt-pbm-interim-report-2024
- Profile slug
- pbm-interim-report-2024
- Docket
- Not listed
- License
- CC BY 4.0
Official-record interpretation boundary
A record dossier preserves what one dated official source says and the observatory context linked to it. It does not convert allegations into findings, findings into economy-wide conclusions, or nearby market indicators into causal effects.
A linked market identifies the observatory context assigned to this record. It is not necessarily the relevant antitrust market alleged or adjudicated in the official matter.